Eloxx Pharmaceuticals Q3 2026 net loss widens to $5.54M
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Eloxx Pharmaceuticals, Inc. (ELOX) reported a third-quarter 2026 net loss of $5.543 million, compared with a $0.351 million net loss in the same quarter of 2025. For the first nine months of 2026, net loss was $13.799 million versus $3.951 million a year earlier. Third-quarter research and development expenses were $4.028 million, compared with a $0.250 million net credit in 2025, while general and administrative expenses were $1.925 million versus $0.535 million.
Cash and cash equivalents were $56.264 million as of September 30, 2026, compared with $62.0 million as of June 30, 2026. Eloxx said it believes its cash will be sufficient to fund operations into 2028.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate point. Forward-looking: it has not happened yet and may not happen.Funding outlook: Eloxx believes cash will fund operations into 2028.
Negative
- Moderate pointQuarterly net loss: $5.543 million, versus $0.351 million in 2025.
Filing Explained
Eloxx’s update places its two disclosed rare-kidney-disease programs at different stages: the Phase 2b EXACT study has dosed its first two patients, while the EXPRESS study has IND clearance and a finalized protocol.
8-K Event Classification
Key Figures
Key Terms
Phase 2b EXACT study medical
IND clearance regulatory
readthrough of premature stop codons technical
nonsense mutation Alport syndrome medical
autosomal dominant polycystic kidney disease medical
Earnings Snapshot
Eloxx believes its cash and cash equivalents will be sufficient to fund operations into 2028.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What was ELOX’s net loss in Q3 2026?
How much cash did ELOX report at September 30, 2026?
AI-generated analysis. How Rhea-AI works. Not financial advice.